Lobbying Relationship


Akebia Therapeutics, Inc.

Therapeutic solutions leveraging the potential of hypoxia inducible factor (HIF) biology More records

Lobbying firm


Law firm More records

  • Reverse CMS decision to remove Auryxia from the Part D formulary.

Duration: to

General Issues: Health Issues, Medicare/Medicaid


Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Heide Bajnrauh Sen McCain LSA, 96-97
Todd Tuten Rep Michael Bilirakis; 91-92, 93-95, 98-01
Julie Nolan Deputy CoS and LD, Nov.17-Nov. 18; LD, Nov.16-17; LA Oct. 15-16 to Rep. Patrick Meehan; Staff Asst, Sen. Richard Lugar Jan. 06-Jan. 07.
John Jonas n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.


Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page